A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

A Trial to Compare the Injection Site Pain Experience of 0.25 mg Semaglutide sc Administered by 2 Different Products

This study in healthy men and women compares the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (sc, under the skin). Participants will receive 2 single doses of semaglutide 0.25 mg on 1 day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers Diabetes Mellitus, Type 2; Healthy Volunteers Overweight; Healthy Volunteers Obesity
• Intervention / Treatment: Drug: Semaglutide (administered by DV3396 pen); Drug: Semaglutide (administered by PDS290 pen)

• Study Type: Interventional
• Enrollment (Actual): 103
• Phase: Phase 2

Contacts and Locations

Study Locations

• Netherlands
  • Groningen, Netherlands, 9728 NZ
    • Novo Nordisk Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
• Male or female subjects, aged 18 to 75 years (both inclusive) at the time of signing informed consent.
• BMI equal to or above 25.0 kg/m^2
• Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the Investigator.

Exclusion Criteria:

• Known or suspected hypersensitivity to the study product or related products.
• Previous participation in this study. Participation is defined as having received investigational product.
• Woman who is pregnant or breast-feeding or intends to become pregnant within 4 weeks after administration of the study drug, or is of childbearing potential and not using highly effective contraceptive methods with her fertile male sexual partner
• Participation in a drug study within 60 days prior to drug administration in the current study. Participation in more than 4 other drug studies in the 12 months prior to drug administration in the current study.
• Any disorder that in the Investigator's opinion might jeopardize subject's safety, evaluation of results, or compliance with the protocol.
• Glycosylated haemoglobin (HbA1c) equal to or above 6.5% at screening.
• Supine blood pressure at screening (after resting for at least 5 minutes) outside the range of 90 to 160 mmHg for systolic or 45 to 89 mmHg for diastolic.
• Supine pulse rate (as part of vital signs) (after resting for at least 5 minutes) outside the range of 40 to 100 beats per minute.
• Use of prescription medicinal products or non-prescription drugs or herbal products, except routine vitamins, topical medication, contraceptives, and occasional use of paracetamol (paracetamol not allowed within 24 hours prior to drug administration), within 14 days prior to drug administration.
• Diagnostic test results positive for human immunodeficiency virus (HIV)-1 or HIV-2 infection.
• Diagnostic test results positive for hepatitis B or hepatitis C infection.
• Mental incapacity, language barriers, or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or cooperation during the study as judged by the Investigator.
• Average intake of more than 21 units of alcohol per week for male subjects and more than 14 units per week for female subjects: 1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits.
• Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at screening and admission to the clinical research center.
• Use of tobacco and nicotine products, defined as any of the below:
• Smoking more than 1 cigarette or the equivalent per day on average
• Not able or willing to refrain from smoking and the use of nicotine substitute products during the in-house period
• Blood donation, plasma donation or blood draw (as declared by the subject or reported in the medical records):
• In excess of 400 mL within the past 90 days prior to the day of screening
• In excess of 50 mL within the past 30 days prior to the day of screening
• Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by the subject or reported in the medical records)
• Subjects with a history of malignant neoplasms within the past 5 years prior to screening.
• Presence or history of pancreatitis (acute or chronic; as declared by the subject or reported in the medical records).
• Subject is not able to understand and read English or Dutch, or subject is not able to understand and comply with the study requirements.
• Subject depends on the Sponsor, the Investigator, or the study center, or subject is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the study.
• Vulnerable subject (eg, person kept in detention) who may have an increased likelihood of being wronged or of incurring additional harm.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: DV3396 followed by PDS290; The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach	Drug: Semaglutide (administered by DV3396 pen); Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day; Drug: Semaglutide (administered by PDS290 pen); Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
EXPERIMENTAL: PDS290 followed by DV3396; The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach	Drug: Semaglutide (administered by DV3396 pen); Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day; Drug: Semaglutide (administered by PDS290 pen); Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intensity of Injection Site Pain	The intensity of injection site pain was measured on a visual analogue scale (VAS). The VAS consists of a horizontal 100 millimetres (mm) line where 0 mm corresponded to no pain and 100 mm corresponded to unbearable pain. After each injection, the participants rated their pain perception at the VAS by marking a vertical line across the 100 mm line. The distance (mm) between the endpoint "no pain" and the vertical line on the VAS was recorded and analysed.	After 1 minute of each injection (Day 1)

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S

Publications and helpful links

General Publications

• Snitker S, Andersen A, Lindskov PS, van Marle S, Sode BF, Sparre T. Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector. Diabetes Obes Metab. 2022 Aug;24(8):1643-1646. doi: 10.1111/dom.14718. Epub 2022 May 20. No abstract available.

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 27, 2019
• Primary Completion (ACTUAL): July 28, 2019
• Study Completion (ACTUAL): September 4, 2019

Study Registration Dates

• First Submitted: June 25, 2019
• First Submitted That Met QC Criteria: July 2, 2019
• First Posted (ACTUAL): July 5, 2019

Study Record Updates

• Last Update Posted (ACTUAL): August 4, 2020
• Last Update Submitted That Met QC Criteria: July 24, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Overnutrition; Nutrition Disorders; Body Weight; Diabetes Mellitus, Type 2; Obesity; Overweight
• Other Study ID Numbers: INS-4582; 2019-002284-10 (REGISTRY: European Medicines Agency (EudraCT)); U1111-1233-9590 (OTHER: World Health Organization (WHO))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No